Earkart Limited Announces Board Decisions and Q2 FY2026 Results Post-IPO

1 min read     Updated on 15 Nov 2025, 12:14 AM
scanx
Reviewed by
Jubin VergheseScanX News Team
Overview

Earkart Limited (BSE: 544549) held a board meeting on November 14, 2025, approving several important measures. The board authorized an ESOP scheme application, appointed N Kothari & Associates as Secretarial Auditor for FY 2025-26, and approved unaudited financial results for Q2 and H1 ending September 30, 2025. The company completed its IPO, issuing 3,315,000 equity shares at Rs 135 per share, increasing its paid-up capital to Rs 1,375.39 lakhs and generating a share premium of Rs 4,097.65 lakhs. Earkart has committed to transparency by ensuring timely disclosure of these developments to BSE Limited and making detailed financial results available on its website.

24691497

*this image is generated using AI for illustrative purposes only.

Earkart Limited (BSE: 544549), a recently listed company, has made several key announcements following its board meeting held on November 14, 2025. The company, which completed its Initial Public Offering (IPO) earlier this year, has taken significant steps in corporate governance and financial reporting.

Board Approvals and Appointments

The board of directors has approved the following measures:

  1. ESOP Scheme Authorization: The board has authorized an in-principle application for the issuance of Employee Stock Ownership Plan (ESOP) under the "Earkart ESOP Scheme 2025". This move is likely aimed at aligning employee interests with the company's long-term growth.

  2. Secretarial Auditor Appointment: N Kothari & Associates has been appointed as the Secretarial Auditor for the fiscal year 2025-26. The firm, registered with the Institute of Company Secretaries of India (ICSI), brings expertise in compliance audit, assurance services, and legal advisory.

Financial Results

The board has approved the unaudited standalone financial results for the quarter and half-year ended September 30, 2025. These results have been reviewed by the company's Peer Reviewed Auditor, M/s Gianender & Associates, Chartered Accountants.

Post-IPO Capital Structure

Earkart Limited successfully completed its IPO during the reported period, with the following details:

Particulars Details
Number of Equity Shares Issued 3,315,000
Issue Price per Share Rs 135.00
Increase in Paid-up Capital From Rs 1,043.89 lakhs to Rs 1,375.39 lakhs
Share Premium Generated Rs 4,097.65 lakhs

This capital raise has significantly bolstered the company's financial position, providing resources for potential growth initiatives.

Compliance and Transparency

In line with regulatory requirements, Earkart Limited has ensured timely disclosure of these developments to the BSE Limited. The company has also stated that the detailed financial results and related documents will be made available on its official website ( https://earkart.com ), demonstrating a commitment to transparency for its shareholders and the investing public.

The board meeting, which commenced at 3:00 P.M. and concluded at 6:00 P.M. on November 14, 2025, marks a significant milestone for Earkart Limited as it navigates its post-IPO phase. Investors and market watchers will likely keep a close eye on how the company utilizes its newly raised capital and implements its ESOP scheme in the coming months.

like20
dislike

Earkart's OMNI Platform Showcased at Global Otolaryngology Conference

1 min read     Updated on 27 Oct 2025, 05:31 PM
scanx
Reviewed by
Naman SharmaScanX News Team
Overview

Earkart Limited presented its next-generation OMNI platform, a remote diagnostic solution for ENT care, at the world's largest otolaryngology conference in Indianapolis, USA. The event, attended by over 5,000 specialists from more than 75 countries, featured live demonstrations of OMNI's real-time diagnostics and remote consultation capabilities. The platform garnered significant interest from ENT specialists, audiologists, and healthcare leaders, suggesting potential for expansion across North America, Europe, the Middle East, and emerging healthcare markets. Earkart, a hearing healthcare solutions provider, operates with a business model combining technology, accessibility, and social impact, with a revenue split of 69% government and 29% private.

23112082

*this image is generated using AI for illustrative purposes only.

Earkart Limited, a hearing healthcare solutions provider, presented at the world's largest otolaryngology conference held in Indianapolis, USA, from October 11-13, 2025. The company introduced its next-generation OMNI platform, a remote diagnostic solution for ENT care, to over 5,000 specialists from more than 75 countries.

OMNI Platform Presentation

Earkart's booth featured live demonstrations of OMNI's real-time diagnostics and remote consultation capabilities. The platform's features attracted interest from ENT specialists, audiologists, and healthcare leaders attending the event.

Key Highlights of Earkart's Participation

Aspect Details
Event World's largest otolaryngology conference
Location Indianapolis, USA
Date October 11-13, 2025
Attendees Over 5,000 specialists from 75+ countries
Product Introduced OMNI platform (remote diagnostic solution)
Key Features Real-time diagnostics, remote consultation
Interest Generated Increased registration forms, specialists expressed adoption interest

OMNI's Potential Markets

The interest in OMNI suggests potential for expansion across various markets:

  • North America
  • Europe
  • Middle East
  • Emerging healthcare markets

Earkart's Business Overview

Earkart Limited operates with a business model combining technology, accessibility, and social impact:

Business Aspect Details
Revenue Split 69% government, 29% private
Clinic Network 49 shop-in-shop clinics across 22 cities
Product Portfolio Hearing aids under brands EQFY, Fame, and Radius
Proprietary Technology OMNI Audiometer
Certifications ISO 13485, CDSCO, and BIS compliance
Manufacturing Facility in Noida with 4,500 sq. ft. production area

The company has a presence in government supply channels via GeM and ALIMCO, along with a footprint in Tier 2 and Tier 3 cities.

The showcase of OMNI at this global conference represents a notable event for Earkart in the ENT care sector.

like17
dislike
Explore Other Articles